The latest Kaiser Family Foundation tracking survey of registered voters finds the ACA is only one of many issues considered in the choice of who they vote for.
Despite the debate about the future of the Affordable Care Act (ACA) among candidates running for president, the latest monthly healthcare tracking poll conducted by the Kaiser Family Foundation found that the ACA is only one of many issues affecting voters’ decision making on who they will support for president.
The poll of working-age adults with insurance found that 23% said it is extremely important, but only 4% of surveyed voters said it is the most important issue. Across all issues included in the poll, terrorism and the economy are the top two issues for voters at this point in the election cycle.
No matter which political party respondents identified with (including Independent), the ACA never ranked higher than fourth in what voters say will be their most important issue. Among registered voters, the ACA is the eighth in importance to voters. Among issues ranking higher are the personal cost of healthcare and health insurance, which 28% of voters say is extremely important to their vote.
The poll captured experiences of all insured Americans 18 to 64 years, not only those enrolled in ACA marketplace plans. It was conducted January 13 to 19, 2016, among a nationally representative random digit dial telephone sample of 1204 people. Interviews were conducted in English and Spanish by landline (481) and cell phone (723). The margin of sampling error is ±3 percentage points for the full sample.
Overall, public opinion on the law is closely split, with 44% having an unfavorable view and 41% having a favorable one. The poll found that the vast majority of respondents (87%) say there are “very” or “somewhat” satisfied with the choice of doctors in their plan’s network; 4% say they are “very dissatisfied.” Among this group, 12% say they had to change doctors in the past 12 months because their doctor wasn’t covered by their health insurance plan. This includes 5% who say the change was a big problem, 5% who say it was a small problem, and 1% who says it was not a problem.
Overall, most nonelderly Americans with insurance (74%) say that health insurance is worth the money it costs and 61% say their plan is an excellent or good value for what they pay for it.
Dr Dalia Rotstein: Physicians Must Be Aware MS Affects People of All Backgrounds
April 24th 2024Dalia Rotstein, MD, MPH, emphazises the importance of awareness that multiple sclerosis (MS) impacts patients from various backgrounds as clinicians think through ways to improve access to care and research efforts in MS.
Read More
Navigating Health Literacy, Social Determinants, and Discrimination in National Health Plans
February 13th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the February 2024 issue of The American Journal of Managed Care® about their findings on how health plans can screen for health literacy, social determinants of health, and perceived health care discrimination.
Listen
Polatuzumab Vedotin and R-CHP Appropriate for Untreated DLBCL
April 24th 2024Population pharmacokinetic and exposure-response analyses revealed a favorable benefit-risk profilane for the treatment combination of polatuzumab vedotin and rituximab, cyclophosphamide, doxorubicin, and prednisone (R-CHP).
Read More
Drs Raymond Thertulien, Joseph Mikhael on Racial Disparities in Multiple Myeloma Care Access
December 28th 2023In the wake of the 2023 American Society of Hematology Annual Meeting and Exposition, Raymond Thertulien, MD, PhD, of Novant Health, and Joseph Mikhael, MD, MEd, FRCPC, FACP, chief medical officer of the International Myeloma Foundation, discussed health equity research highlights from the meeting and drivers of racial disparities in multiple myeloma outcomes.
Listen
Award-Winning Poster Presentations From AMCP 2024
April 23rd 2024At the Academy of Managed Care Pharmacy (AMCP) 2024 annual meeting, multiple poster presentations concerned with health equity, data collection, glucagon-like peptide-1 agonists, and more were acknowledged for their originality, relevance, clarity, bias, and quality.
Read More